# Editas Wins Australia Clearance as Wells Fargo Upgrades Rating

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/28282
Published: 2026-10-08T16:09:11.000Z
Updated: 2026-10-08T16:09:11.000Z
Section: Business

> Australian authorities cleared a Phase 1/2 gene-editing trial, while Wells Fargo moved its Editas rating from Equal Weight to Overweight.

Editas Medicine received Australian clearance for a Phase 1/2 trial of its gene-editing therapy Thursday, while Wells Fargo upgraded the biotech to Overweight from Equal Weight.

The regulatory decision allows the trial to proceed in Australia.

Editas is developing a gene-editing therapy. The trial is in the Phase 1/2 stage.

Wells Fargo’s upgrade moves its rating on Editas from Equal Weight to Overweight. The rating change followed the Australian clearance.